Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Refractory Adrenocortical Carcinoma
NCT00453895Phase 2Completed
- Start
- Jul 2007
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in adrenocortical carcinoma (ACC). Primary endpoint: Assessment of Clinical Benefit Due to Treatment With Sunitinib at 12 weeks. Started Jul 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT00453895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00453895.